3B Blackbio Dx Limited (BOM:532067)
India · Delayed Price · Currency is INR 1,464.85
-16.85 (-1.14%)
At close: Sep 4, 2026
3B Blackbio Dx Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 1,006 | 124.73 | 136.19 | 60.02 | 288.92 |
Cash & Short-Term Investments | 1,006 | 1,006 | 124.73 | 136.19 | 60.02 | 288.92 |
Cash Growth | 706.71% | 706.72% | -8.42% | 126.91% | -79.23% | -17.64% |
Accounts Receivable | - | 500.89 | 365.2 | 362.46 | 339.41 | 299.79 |
Receivables | - | 500.89 | 365.2 | 362.46 | 340.26 | 300.63 |
Inventory | - | 183.78 | 87.42 | 84.27 | 80.44 | 74.35 |
Other Current Assets | - | 235.77 | 744.55 | 651.02 | 661.65 | 151.52 |
Total Current Assets | - | 1,927 | 1,322 | 1,234 | 1,142 | 815.4 |
Property, Plant & Equipment | - | 276.03 | 72.19 | 74.01 | 78.85 | 67.23 |
Long-Term Investments | - | 1,577 | 1,563 | 1,173 | 917.12 | 1,036 |
Other Long-Term Assets | - | 0.26 | - | - | 2.25 | 2.75 |
Total Assets | - | 3,780 | 2,957 | 2,481 | 2,141 | 1,921 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | 69.24 | 19.66 | 39.49 | 33.71 | 35.43 |
Accrued Expenses | - | - | 4.43 | 14.09 | 2.02 | 2.84 |
Short-Term Debt | - | - | - | - | 11.16 | 16.9 |
Current Income Taxes Payable | - | 160 | 148.2 | 108.33 | 84.81 | 99.7 |
Other Current Liabilities | - | 136.23 | 13.59 | 13.44 | 10.15 | 14.14 |
Total Current Liabilities | - | 365.47 | 185.88 | 175.34 | 141.84 | 169.01 |
Long-Term Debt | - | 31.07 | 3.07 | 7.88 | 9.13 | 8.4 |
Long-Term Deferred Tax Liabilities | - | 67.03 | 58.18 | 43.08 | 29.18 | 22.73 |
Other Long-Term Liabilities | - | - | - | 0 | 1.33 | 0.02 |
Total Liabilities | - | 463.57 | 247.14 | 226.31 | 181.48 | 200.15 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 85.68 | 85.68 | 85.68 | 85.66 | 74.92 |
Additional Paid-In Capital | - | - | 88.35 | 88.35 | 88.35 | 92.94 |
Retained Earnings | - | - | 2,508 | 2,054 | 1,756 | 1,360 |
Comprehensive Income & Other | - | 3,158 | 2.44 | 2.44 | 2.44 | 2.44 |
Total Common Equity | 3,244 | 3,244 | 2,684 | 2,230 | 1,933 | 1,530 |
Minority Interest | - | 72.57 | 25.83 | 24.25 | 26.54 | 190.51 |
Shareholders' Equity | 3,316 | 3,316 | 2,710 | 2,255 | 1,959 | 1,721 |
Total Liabilities & Equity | - | 3,780 | 2,957 | 2,481 | 2,141 | 1,921 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 31.07 | 31.07 | 3.07 | 7.88 | 20.29 | 25.3 |
Net Cash (Debt) | 975.13 | 975.13 | 121.66 | 128.31 | 39.73 | 263.62 |
Net Cash Growth | 701.52% | 701.53% | -5.18% | 222.96% | -84.93% | -20.30% |
Net Cash Per Share | 114.48 | 116.41 | 14.20 | 14.97 | 4.64 | 35.19 |
Filing Date Shares Outstanding | 9.1 | 8.35 | 8.57 | 8.57 | 7.51 | 7.51 |
Total Common Shares Outstanding | 9.1 | 8.35 | 8.57 | 8.57 | 7.51 | 7.51 |
Working Capital | - | 1,561 | 1,136 | 1,059 | 1,001 | 646.4 |
Book Value Per Share | 388.37 | 388.37 | 313.27 | 260.32 | 257.40 | 203.81 |
Tangible Book Value | 3,244 | 3,244 | 2,684 | 2,230 | 1,933 | 1,530 |
Tangible Book Value Per Share | 388.37 | 388.37 | 313.27 | 260.32 | 257.40 | 203.81 |